We are engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Our product portfolio is organized into five distinct segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. The pharmaceutical products marketed under the “Goldline” brand are not manufactured by our Company. Instead, we enter into contractual arrangements with third-party manufacturers, who produce the products based on our market research, demand analysis, and specifications. These contractual arrangements ensure that all products meet the requisite quality standards and regulatory norms.The products are marketed and sold exclusively under the “Goldline” brand. Our customers primarily comprise distributors, who further supply to retailers and wholesalers, forming the main channel of distribution to the end-users. Presently, we maintain contractual arrangements with 15 manufacturers and 7 distributors, ensuring a stable supply chain and consistent market presence.Our Company also extend comprehensive material supply and procurement support to hospitals and healthcare partners. Through our promoter group entities as Numerius Healthcare Pvt Ltd (Formerly Known As Enrich Healthcare & PSPL International) & Activista Healthcare Pvt Ltd (Formerly Known As Gold N Gold Distributors). Our Company manage trading and supply chain operations, thereby ensuring reliable procurement, seamless distribution, and logistical efficiency.Our Promoters, Mr. Amol Laxmikant Mujumdar and Mr. Swapan Premprakash Khandelwal, with 25 years and 30 years of experience respectively in pharmaceutical marketing and supply chain management, have been instrumental in shaping the growth and strategic direction of the Company. Their expertise continues to drive our business expansion and operational resilience.
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | 1350000 crores |
| Non-Institutional Investors (NIIs | 15% | 405000 crores |
| Retail Individual Investors (RIIs) | 35% | 945000 crores |
Goldline Pharmaceutical Ltd’s total income 0 by 0.00% and total expenses 0 by 0.00%, resulting in an EBITDA 5.83 by 35.58% and a profit after tax (PAT) 0 by 0.00% between March 31, 2025 and March 31, 2026.
2.1931 March 2026 | 4.331 March 2025 | 5.8331 March 2024 |
5.83
5
5
4
3
3
2
2
1
1
0
Experienced promoters and management team.
Asset-light business model through third-party manufacturing.
Diversified pharma product portfolio across multiple therapeutic categories.
Scalable distribution-led business model.
Established supplier and distributor relationships.
Presence across multiple Indian states.
| Allotment Date | Listing Date |
|---|---|
| 15 May '26 | 19 May '26 |
| Minimum Lot Size | 3000 shares |
| Maximum Lot Size (Retail) | 9000 shares |
The lot size of Goldline Pharmaceutical Ltd ipo has been designed to ensure broad participation while maintaining optimal price discovery.
103 F-1 Leela Apartment Shilpa Hsg Society Nagpur
Bigshare Services Pvt.Ltd.